EP0186001A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Interference-resistant liposome specific binding assay
Assignee: Bayer Corp
•
Filing: 1985-12-05
•
Granted: —
•
Expires: 2005-12-05
Abstract
Abstract A method and reagent composition provide for the removal or blocking of serum interferences in liposome immunoassays. A carrier or liposome exhibiting at least one domain of phosphoryl ester groupings different from those of the marker liposome is introduced into the reaction mixture, whereby endogenous interfering species competitively bind to such carrier or liposome rather than to the marker liposome. Also, soluble phosphoryl ester groupings can be introduced into the reaction mixture which react to such endogenous species and further reduce serum interferences.
Inventors
- 👤 Robert H. Adolfsen
- 👤 Eddie Hedaya
- 👤 Amy C. Lam Mak
- 👤 Moshe Schwarzberg
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-05 21:38
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/531; G01N33/532; G01N33/58; G01N33/585; G01N33/586; Y; Y10; Y10S; Y10S435/00; Y10S435/962; Y10S436/00; Y10S436/821; Y10S436/825; Y10S436/829
Claims Analysis
Total Claims: 31
Claim 1
Independent Claim
63 words
1 . A method for reducing interference by endogenous liposome binding species in a liposome immunoassay wherein a first marker liposome is reacted with a sample containing an analyte to be assayed in the presence of a specific binding partner to form a reaction mixture which comprises adding a carrier capable of competively binding said endogenous liposome- binding species to said reaction mixture.
Claim 2
Dependent Claim
63 words
1 . A method for reducing interference by endogenous liposome binding species in a liposome immunoassay wherein a first marker liposome is reacted with a sample containing an analyte to be assayed in the presence of a specific binding partner to form a reaction mixture which comprises adding a carrier capable of competively binding said endogenous liposome- binding species to said reaction mixture.
Claim 3
Dependent Claim
36 words
A method as in Claim 1, wherein said carrier is an insoluble particle and comprising the further step of binding phosphoryl ester groupings to said particle prior to mixing of said carrier in said reaction mixture.
Claim 4
Dependent Claim
15 words
A method as in Claim 2, wherein the particle is formed of a polymeric material.
Claim 5
Dependent Claim
15 words
A method as in Claim 1, wherein the carrier is formed as a second liposome.
Claim 6
Dependent Claim
36 words
A method as in Claim 4, wherein the carrier is formed as a second liposome, said second liposome having a phosopholipid composition different than that of said first liposome to provide at least one different domain.
Claim 7
Dependent Claim
45 words
A method as in Claim 1, wherein the carrier is formed as a second liposome, and incorporates a cardiolipin within the membrane of said second liposome, so as to provide at least one different domain, prior to mixing of said carrier into said reaction mixture.
Claim 8
Dependent Claim
64 words
7 . A method as in Claim 1, wherein the carrier is formed as a second liposome, and incorporates a second ligand or ligand analogue of the analyte which is non-cross-reactive with a first ligand or ligand analogue, within the membrane of said second liposome, so as to provide at least one different domain, prior to mixing of said carrier into said reaction mixture.
Claim 9
Dependent Claim
15 words
A method as in Claim 1, wherein the carrier is formed as a soluble substance.
Claim 10
Dependent Claim
45 words
A method as in Claim 1, wherein the carrier is formed as a second liposome and incorporates a protein within the membrane of said second liposome, so as to provide at least one different domain, prior to mixing of said carrier into said reaction mixture.
Claim 11
Independent Claim
33 words
A method as in Claims 2 or 8, wherein the soluble substance is soluble ester of a phosphoric acid and is introduced into said reaction mixture to provide phosphoryl ester groupings in solution.
Claim 12
Dependent Claim
12 words
A method as in Claim 10, wherein the ester is phosphoryl choline.
Claim 13
Dependent Claim
33 words
A method as in Claim 1, wherein said marker is an enzyme encapsulated with said first liposome and including the further step of mixing into said reaction mixture a substrate for said enzyme.
Claim 14
Dependent Claim
50 words
A method as in Claim 12, wherein said marker is an enzyme encapsulated within said first liposome and including the further step of mixing into said reaction mixture a substrate for said enzyme and a substance which is reactive with the product resulting from the enzymatic conversion of said substrate.
Claim 15
Dependent Claim
22 words
A method as in Claim 13, wherein said reactive substance is an enzyme different from said enzyme encapsulated within said first liposome.
Claim 16
Dependent Claim
22 words
A method as in Claim 12, wherein said enzyme encapsulated within said first liposome is galactosidase and said substrate is a galactoside.
Claim 17
Dependent Claim
18 words
A method as in Claim 10, wherein said soluble phosphoric esters are nucleosides or phosphoryl esters of carbohydrates.
Claim 18
Dependent Claim
39 words
A composition for use in a liposome immunoassay for determining a ligand in a liquid sample, which composition comprises a carrier expressing at least one domain of phosphoryl ester groupings different from said domains expressed by said first liposome.
Claim 19
Dependent Claim
39 words
A composition for use in a liposome immunoassay for determining a ligand in a liquid sample, which composition comprises a carrier expressing at least one domain of phosphoryl ester groupings different from said domains expressed by said first liposome.
Claim 20
Dependent Claim
77 words
A composition as in Claim 17 wherein the assay contains: (a) a binding partner for said ligand; (b) a selectively accessible first liposome having a ligand or cross-reactive ligand analogue incorporated within its membrane, expressing predetermined domains of phosphoryl ester groupings and containing a marker to indicate modification of said first liposome accessibility; and (c) a substance which modifies vesicle accessibility in response to binding of said membrane incorporated ligand or ligand analogue with said binding partner.
Claim 21
Dependent Claim
22 words
The composition of Claims 17 or 18, wherein said carrier is a second liposome having different phospholipid composition than said first liposome.
Claim 22
Dependent Claim
20 words
The composition of Claims 17 or 18, wherein said carrier is a second liposome incorporating a cardiolipin within its membrane.
Claim 23
Dependent Claim
27 words
The composition of Claim 17 or 18, wherein said carrier is a second liposome incorporating a non-cross-reactive analogue of the ligand to be assayed within its membrane.
Claim 24
Dependent Claim
17 words
The composition of Claim 17 or 18 containing at least one soluble ester of a phosphoric acid.
Claim 25
Dependent Claim
30 words
The composition of Claim 17 or 18, wherein the carrier is a second liposome incorporating a protein within its membrane and/or the first liposome incorporates a protein within its membrane.
Claim 26
Dependent Claim
21 words
The composition of Claim 22, wherein one soluble ester is phosphoryl choline, a nucleoside or a carbohydrate ester of phosphoric acid.
Claim 27
Dependent Claim
18 words
The composition of Claim 18 wherein said marker is encapsulated within said first liposome and is an enzyme.
Claim 28
Dependent Claim
45 words
The composition of Claim 25 wherein said marker is an enzyme and further including a substrate for said enzyme and an additional substance reactive with the product resulting from the enzymatic conversion of said substrate, to indicate a change in accessibility of said first liposome.
Claim 29
Dependent Claim
12 words
The composition of Claim 26, wherein said additional substance is another enzyme.
Claim 30
Dependent Claim
16 words
The composition of Claim 26, wherein said additional substance is another enzyme co-encapsulated within said liposome.
Claim 31
Dependent Claim
21 words
The composition of Claim 18 wherein said marker is a substrate for an enzyme and is encapsulated within said first liposome.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.